Ocrevus 300 MG/10 ML vial 10ML
Ended Awarded Last action
- Contract number
- SPE2DR26F47UB
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,638
Award facts
- Contract value 100% obligated
- $25,637.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $25,637.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 28, 2026, for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials. This non-set-aside contract represents a single delivery order with an ultimate completion date of February 19, 2026, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical (SPE2DX), valued at up to $999,999,999.00 and extending through December 2026, which serves as the primary vehicle for supplying comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving federal medical procurement needs across the Defense Health System. The company has demonstrated consistent capability in fulfilling competitive federal contracts for diverse pharmaceutical products across multiple therapeutic domains. This delivery order for Ocrevus, a specialty immunosuppressant medication used in treating multiple sclerosis, exemplifies the company's role in supplying critical brand-name biologics through the Defense Logistics Agency's medical supply chain to support military treatment facilities and veteran healthcare programs.
Quick answers
Who was awarded contract SPE2DR26F47UB?
SPE2DR26F47UB was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26F47UB worth?
The government has obligated $25,638 on SPE2DR26F47UB.
Is contract SPE2DR26F47UB an order under another contract?
Yes. SPE2DR26F47UB is a delivery order under SPE2DR25D2101, an indefinite delivery contract.
Was contract SPE2DR26F47UB competed?
The extent of competition for SPE2DR26F47UB was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award